CG Oncology, Inc. (NASDAQ:CGON) Stock Has Average Target Price of $87.50 According to Analysts

Posted by George Bondi on Oct 14th, 2026

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $87.50.

Several equities analysts have commented on the company. Wall Street Zen downgraded CG Oncology from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a report on Friday, July 17th. Piper Sandler upped their price objective on CG Oncology from $82.00 to $85.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price objective on shares of CG Oncology in a research note on Wednesday, July 29th. Finally, Truist Financial raised their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a report on Friday, August 7th.

View Our Latest Stock Analysis on CG Oncology

Insiders Place Their Bets

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $72.98, for a total transaction of $72,980.00. Following the sale, the director directly owned 1,000 shares of the company’s stock, valued at $72,980. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.80% of the stock is owned by insiders.

Hedge Funds Weigh In On CG Oncology

Several large investors have recently modified their holdings of CGON. Fiduciary Financial Advisors acquired a new position in shares of CG Oncology in the 2nd quarter worth approximately $28,000. NFSG Corp bought a new stake in shares of CG Oncology in the 1st quarter valued at $34,000. Fifth Third Bancorp bought a new stake in shares of CG Oncology in the 1st quarter valued at $74,000. GAMMA Investing LLC increased its position in shares of CG Oncology by 47.9% during the third quarter. GAMMA Investing LLC now owns 1,081 shares of the company’s stock worth $77,000 after buying an additional 350 shares during the period. Finally, KBC Group NV acquired a new stake in shares of CG Oncology during the first quarter worth $78,000. Institutional investors own 26.56% of the company’s stock.

CG Oncology Stock Performance

Shares of NASDAQ:CGON opened at $62.40 on Friday. CG Oncology has a 52-week low of $35.80 and a 52-week high of $80.97. The company has a market capitalization of $5.53 billion, a PE ratio of -23.20 and a beta of 0.28. The company has a fifty day moving average of $73.04 and a 200-day moving average of $69.05.

CG Oncology (NASDAQ:CGON – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.24). The firm had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.36 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. On average, equities analysts forecast that CG Oncology will post -3.31 EPS for the current fiscal year.

About CG Oncology

(Get Free Report)

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on developing therapies for bladder cancer and other cancers of the urinary tract. The company’s research centers on cancer-directed immunotherapies designed to stimulate the immune system and target tumor cells.

Its lead product candidate is cretostimogene grenadenorepvec, an intravesical oncolytic adenovirus being studied for the treatment of non-muscle-invasive bladder cancer (NMIBC). The therapy is designed to be delivered directly into the bladder, where it may selectively infect tumor cells and activate an immune response against cancer.

CG Oncology has evaluated cretostimogene in clinical studies involving patients with NMIBC, including individuals whose disease has not responded adequately to Bacillus Calmette-Guérin (BCG), a standard bladder cancer treatment.